Medical Services

BRAF-mutated melanoma and colon cancer are aggressive malignancies caused by mutations in the BRAF gene, predominantly the V600E variant. This genetic mutation causes cells to grow uncontrollably by excessively activating the MAPK/ERK signalling system. BRAF mutations are found in about half of people with melanoma and in around 10% of people with colon cancer. They are generally connected to a poor prognosis.

It is critical to find these malignancies early since they can grow quickly. Genetic testing and other advanced diagnostic technologies make it possible to find the exact mutation, which lets doctors make personalised treatment programmes. Targeted medicines like BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib) have changed the way we treat cancer by directly inhibiting the aberrant signalling pathway, reducing the disease's growth, and raising the chances of survival.

In colon cancer, BRAF mutations frequently signify resistance to specific standard chemotherapies, rendering molecular profiling crucial for informing therapy choices. Combination medicines and ongoing clinical trials are broadening treatment choices for patients with resistant or advanced illness.
Regular follow-up and monitoring are essential for finding recurrences early. The best results come from multidisciplinary care that includes oncologists, geneticists, and surgeons. As research continues, treatment for tumours with BRAF mutations gets better and more tailored to each patient, giving them new hope.